Scorched by cover-up claims in nationwide opioid litigation, Endo Pharmaceuticals is hoping for heroics from a Skadden squad that is belatedly revealing vast volumes of drug marketing records, a strategy that could simultaneously snuff out some discovery deficiencies and fuel new doubts about the drugmaker’s initial transparency.<\/p>\n
“Where the discovery is in the infancy, there’s an argument of, ‘No harm, no foul,'” Napoli Shkolnik PLLC partner Hunter J. Shkolnik, one of the nation’s leading opioid attorneys for local governments, told Law360. “But I’ve got to tell you, there’s enough cases that are of advanced age that they have a hurt coming.”<\/p>\n
The Napoli Shkolnik partner, told Law360 that Endo is seemingly trying to make amends, but that its “lawyers’ lack of proper conduct and discovery has jeopardized them in this litigation going forward.”<\/p>\n
“They brought Skadden in to do this discovery clean-up. And it’s turning out it’s worse than we saw. There’s millions of pages and items that were not produced. So it’s going to get ugly,” Shkolnik said. He then took a short pause and offered a different adjective: “Uglier.”<\/p>\n